miR-449a inhibits cell proliferation, migration, and inflammation by regulating high-mobility group box protein 1 and forms a mutual inhibition loop with Yin Yang 1 in rheumatoid arthritis fibroblast-like synoviocytes

Yongsong Cai 1,2 †, Congshan Jiang 3 †, Jialin Zhu 2, Ke Xu 2, Xiaoyu Ren 2, Lin Xu 4, Peijing Hu 5, Bo Wang 6, Qiling Yuan 1, Yuanxu Guo 3, Jian Sun 3, Peng Xu 2* and Yusheng Qiu 1*

Abstract

Background: We previously found that high-mobility group box protein 1 (HMGB1) promoted cell proliferation, migration, invasion, and autophagy in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), but little is known about its regulatory mechanism. The aim of this study was to investigate the regulatory mechanism of HMGB1 at the posttranscription level.

Methods: Real-time qPCR, CCK-8 cell proliferation assay, transwell cell migration assay, enzyme-linked immunosorbent assay (ELISA), and western blotting were used in this study. The targeting relationship between miRNA and mRNA was presented by the luciferase reporter assay.

Results: MiR-449a was downregulated in RA synovial tissue and inhibited RA-FLS proliferation, migration, and IL-6 production. MiR-449a directly targeted HMGB1 and inhibited its expression. Yin Yang 1 (YY1) negatively regulated miR-449a expression and formed a mutual inhibition loop in RA-FLS. MiR-449a inhibited TNFα-mediated HMGB1 and YY1 overexpression and IL-6 production.

Conclusions: Our results reveal the regulatory mechanism of HMGB1 in RA and demonstrate that miR-449a is a crucial molecule in RA pathogenesis and a suitable candidate for miRNA replacement therapies in RA.

Keywords: miR-449a, Rheumatoid arthritis, Fibroblast-like synoviocytes, Proliferation, Inflammation, High-mobility group box protein 1

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by synovial hyperplasia and joint destruction [1]. The understanding of the pathogenic mechanisms of RA and treatments for RA have been greatly improved in the last decade, but there is still no cure for RA [2]. Accumulating evidence indicates that RA fibroblast-like synoviocytes (RA-FLS) play a key role in the pathogenesis of RA [3].

Studies have found that microRNAs (miRNAs) control various cellular processes and play an important role in different diseases, including RA [4, 5]. Recently, several miRNAs were observed to be abnormally expressed in RA, and some of which affected RA-FLS cell proliferation, inflammation, or cellular signaling pathways [6–8]. MiR-449a, located on chromosome 5q11, has been reported to be dysregulated in various diseases and influences cell apoptosis, proliferation, migration, and inflammation by regulating the expression of various genes [9–14]. Our previous research found that miR-449a expression was downregulated in RA synovial tissue compared with osteoarthritis (OA) tissue. However, little is known about the function of miR-449a in RA.

High-mobility group box protein 1 (HMGB1) is a highly conserved chromatin-binding nuclear protein that has been confirmed to play important roles in many diseases [15–17]. Our previous studies found that HMGB1 expression was increased in RA synovial tissue and that HMGB1 promoted cell proliferation, migration, invasion, and autophagy in RA-FLS [18, 19]. Therefore, exploring the molecular mechanisms of HMGB1 dysregulation in RA may help us better understand the pathogenesis of RA. HMGB1 has been reported to be regulated by miRNAs in some diseases [20–24], but whether the overexpression of HMGB1 in RA is related to dysregulated miRNAs remains unknown.

In the present study, we showed that miR-449a expression was downregulated in RA synovial tissue. miR-449a inhibited RA-FLS proliferation, migration, and IL-6 production by targeting HMGB1 and Yin Yang1 (YY1). YY1 negatively regulated miR-449a expression and formed a mutual inhibition loop in RA-FLS. We further found that miR-449a inhibited TNFα-mediated HMGB1 and YY1 overexpression and IL-6 production. miR-449a may be a crucial molecule in RA pathogenesis and a suitable candidate for miRNA replacement therapies in RA.

Methods

Patients and tissue collection

Human synovial tissue samples were obtained from 14 OA patients and 14 RA patients undergoing knee arthroplasty surgery (Department of Joint Surgery, Xi’an Hong Hui Hospital, Xi’an, China). This study was performed with the approval of the human research ethics committee of Xi’an Hong Hui Hospital. All patients fulfilled the American College of Rheumatology (ACR) criteria for the classification of RA or OA and provided informed consent. Information on all patients is summarized in Table 1.

Cell culture

FLS were dissociated from RA synovial tissue specimens, and 3rd to 8th passage cells were used in our study. The cells were grown in DMEM/F12 medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco Life Technologies, USA), 100 units/mL penicillin, and 100 μg/mL streptomycin at 37 °C under 5% CO2.

Oligonucleotides and vector construction

The miR-449a mimics, YY1-siRNA targeting human YY1, and negative control RNAs for both the miRNA and siRNA were chemically synthesized by GenePharma (GenePharma, Shanghai, China). For the expression vector, HMGB1 and YY1 were cloned into pCMV-Blank (Beyotime, Shanghai, China) between the site BamH1 and site EcoRI. We used a bioinformatics analysis to determine that both HMGB1 and YY1 are targets of miR-449a (TargetScan, www.targetscan.org). The linker fragment containing the HMGB1 or YY1 wild-type or the mutant 3’UTR-binding site was synthesized and cloned into the pmirGLO Dual-Luciferase vector (Promega, Madison, WI, USA) between site Sac1 and site Xho1. All the primer sequence information is given in Additional file 1: Table S1.

RNA extraction and quantitative reverse transcription PCR

Total RNA was isolated from the synovial tissue samples and cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol. Two micrograms of total RNA and a Transcriptor cDNA master protocol.

| Table 1 Patient characteristics |
|--------------------------------|
| **Clinical data** | RA | OA |
| Number of patients | 14 | 14 |
| Sex | | |
| Male | 4 | 6 |
| Female | 10 | 8 |
| Age (years) | 59.4 ± 8.2 | 68.9 ± 4.9 |
| Disease duration (years) | 9.3 ± 2.3 | 15.1 ± 3.5 |
| RF (IU/mL) | 123.3 ± 112.2 | 7.1 ± 3.5 |
| ESR (mm/h) | 41.9 ± 12.9 | 22.9 ± 17.3 |
| CRP (mg/l) | 27.6 ± 15.4 | 9.6 ± 9.2 |
| Anti-CCP positive, n | 12/14 | 0/14 |

RF: rheumatoid factor, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, CCP: cyclic citrullinated peptide

Table 1: Patient characteristics

Notes:

Mean ± standard deviation
Luciferase reporter assay
HEK293 cells were cotransfected with 100 ng pmirGLO vectors containing the wild-type or mutant 3′UTR of HMGB1 or YY1 mRNA and 20 nM of miR-449a or 20 nM of the miRNA negative control according to the manufacturer's protocol. After 24 h, luciferase activity was assayed using a Dual-Luciferase Reporter Assay System Kit (Promega, Madison, WI, USA). The relative firefly luciferase activity was normalized to the Renilla luciferase activity.

Western blotting
A 20-μg protein sample was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then electrophoretically transferred to nitrocellulose membranes (Millipore, Billerica, MA, USA). After blocking in 10% nonfat dry milk in Tris-buffered saline/Tween-20 (TBST) for 2 h, the membranes were then incubated with the following primary antibodies overnight at 4 °C: anti-β-actin monoclonal antibody (Bioss, Beijing, China, 1:1000), anti-HMGB1 monoclonal antibody (Abcam, Cambridge, UK, 1:1000), and anti-YY1 monoclonal antibody (Abcam, Cambridge, UK, 1:1000). After washing three times in TBST for 10 min each time, the membranes were incubated with goat anti-rabbit horseradish peroxidase-conjugated secondary antibodies (BOSTER, Wuhan, China, 1:10000) for 1 h at room temperature. After that, the membranes were washed three times with TBST and detected using an electrochemiluminescence (ECL) system (Gene Gnome 5, Synoptics Ltd., UK). The protein levels were normalized to the β-actin protein levels in each sample.

Statistical analysis
Each experiment was repeated three times, and the data were presented as the mean ± standard deviation (SD) or mean with 95% confidence interval (CI). Differences between two groups were analyzed using Student’s t test, or the Mann-Whitney U test for experiments in which the datasets were not normally distributed. All the results were analyzed with GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, USA). P values less than 0.05 were considered statistically significant.

Results
MiR-449a inhibits cell proliferation, migration, and inflammation in RA-FLS
The quantitative PCR (qPCR) results indicated that miR-449a expression was significantly downregulated both in RA synovial tissue and RA-FLS compared with OA (Fig. 1a, b). RA-FLS were transfected with 20 nM miR-449a mimic or 20 nM negative control RNA (miR-NC) for 24 h, 48 h, or 72 h. Cell proliferation was detected via a...
CCK-8 assay. The optical density (OD) value showed that RA-FLS in the miR-449a mimic groups had lower cell proliferation ability than those in the miR-NC groups (Fig. 1c). We also detected the effect of miR-449a on cell migration and IL-6 production in RA-FLS. Both cell migration (Fig. 1d, e) and IL-6 production (Fig. 1f) were significantly inhibited in the RA-FLS transfected with the miR-449a mimic compared with the miR-NC groups. These data demonstrated that miR-449a negatively regulated cell proliferation, migration, and IL-6 production in RA-FLS.

HMGB1 is a direct target of miR-449a in RA

Based on the bioinformatics prediction, we identified a putative binding site for miR-449a in the HMGB1 mRNA 3’UTR (Fig. 2a). The Dual-Luciferase Reporter Assay results showed that miR-449a inhibited the luciferase activity in the cells containing the miR-449a-binding site of the HMGB1 3’UTR but failed to affect the cells containing a mutated version of the miR-449a-binding site of the HMGB1 3’UTR (Fig. 2b), which indicated that miR-449a bound directly to the 3’UTR of the HMGB1 mRNA to suppress translation. After the transfection of RA-FLS with the miR-449a mimic or miR-NC, the expression of HMGB1 was detected. The results revealed that miR-449a inhibited HMGB1 expression at both the mRNA (Fig. 2c) and protein levels (Fig. 2d, e).

qPCR results showed that the expression of HMGB1 was significantly increased in RA synovial tissue compared with OA tissue (Fig. 2f). Immunohistochemistry results also found that HMGB1 was overexpressed in RA synovial tissue (Additional file 2: Figure S1). Furthermore, the
analysis of the expression of miR-449a and HMGB1 mRNA in RA synovial tissue indicated an inverse correlation between the two (Fig. 2g), which suggested that miR-449a might be an important regulator of HMGB1 expression in RA. All the results indicated that HMGB1 was a direct target of miR-449a in RA-FLS.

Overexpression of HMGB1 eliminates the effects of miR-449a in RA-FLS

Given that HMGB1 promotes cell proliferation, migration, invasion, and autophagy in RA-FLS, we wanted to demonstrate whether miR-449a inhibits cell proliferation, migration, and IL-6 production in RA-FLS by inhibiting the expression of HMGB1. After the transfection of RA-FLS with the HMGB1 expression vector (pCMV-HMGB1), the HMGB1 levels were markedly increased at both the mRNA and protein levels (Fig. 3a, b). After the transfection of RA-FLS with the miR-NC or cotransfection of RA-FLS with the miR-449a and pCMV-HMGB1 (miR-449a + HMGB1) or pCMV blank vector (miR-449a + HMGB1-NC), cell proliferation, migration, and IL-6 production were detected. Compared with the miR-NC group, the miR-449a + HMGB1-NC group inhibited RA-FLS proliferation, migration, and IL-6 production, but the overexpression of HMGB1 reduced the effects of miR-449a in RA-FLS (Fig. 3c–f). These data indicated that the miR-449a-mediated inhibition of RA-FLS proliferation, migration, and IL-6 production might be achieved by inhibiting HMGB1 expression.
miR-449a and YY1 form a mutual inhibition loop in RA-FLS

Previous studies found that the transcription factor YY1 was closely related to RA inflammation [25, 26]. YY1 regulates IL-6 transcription in RA and inhibits miR-10a expression, which contributes to the excessive secretion of inflammatory cytokines and the migration and proliferation of RA-FLS [25, 26]. Therefore, we sought to determine whether the dysregulation of miR-449a in RA was also related to YY1. The results showed that the YY1 expression markedly decreased at both the mRNA and protein levels (Fig. 4a, b) after the transfection of RA-FLS with the YY1-siRNA. We also induced YY1 expression using the pCMV-YY1 vector (Fig. 4c, d). After the induction or inhibition of YY1 expression, we detected the levels of miR-449a. As shown in Fig. 4e, compared with the negative control, the YY1-siRNA promoted the expression of miR-449a, and pCMV-YY1 (YY1) inhibited miR-449a expression, indicating that YY1 negatively regulates the expression of miR-449a.

Furthermore, we discovered that the overexpression of miR-449a decreased the level of YY1 at both the mRNA and protein levels (Fig. 4f, g). A luciferase activity assay showed that miR-449a inhibited the luciferase activity in cells containing the miR-449a-binding site of the YY1 3’ UTR but failed to inhibit the luciferase activity in cells containing a mutated version of the miR-449a-binding site of the YY1 3’ UTR (Fig. 4h, i), indicating that YY1 was a direct target gene of miR-449a. These results indicated that miR-449a and YY1 formed a mutual inhibition loop in RA-FLS. We also detected the effect of YY1
on IL-6 production in RA-FLS. As shown in Fig. 4j, the YY1-siRNA inhibited IL-6 production in RA-FLS.

**miR-449a inhibits TNFα-mediated HMGB1 and YY1 overexpression and IL-6 production**

TNFα plays a crucial role in RA pathogenesis. Therefore, we investigated whether TNFα affected HMGB1, YY1 and miR-449a expression and IL-6 production, and the role of miR-449a in this process. After RA-FLS were treated with 10 ng/ml TNFα for 48 h, both the expression of HMGB1 (Fig. 5a) and YY1 (Fig. 5b) and IL-6 production (Fig. 5c) were significantly increased compared with the control-treated RA-FLS, and the expression of miR-449a was decreased (Fig. 5d). We then detected the effects of TNFα in the presence or absence of miR-449a. Interestingly, miR-449a expression weakened TNFα-induced HMGB1 (Fig. 5e) and YY1 (Fig. 5f) expression and IL-6 production (Fig. 5g). These results indicated that miR-449a inhibited TNFα-mediated HMGB1 and YY1 overexpression and IL-6 production.

**Discussion**

In the present study, we determined that the expression of miR-449a was significantly decreased in RA synovial tissue compared with OA tissue. miR-449a inhibited cell proliferation, migration, and IL-6 production by regulating HMGB1 and YY1 expression in RA-FLS. Further study indicated that YY1 negatively regulated miR-449a expression and formed a mutual inhibition loop with miR-449a in RA-FLS. In addition, we also found
that TNFα promoted HMGB1 and YY1 expression and IL-6 production, and miR-449a weakened these effects of TNFα.

Although RA is the most common chronic inflammatory autoimmune joint disease, the pathogenesis of RA remains unclear. RA-FLS, located in the synovial lining, have been proven to play a key role in the RA process [27]. Similar to tumor cells, RA-FLS are a type of special tumor-like cells that are hyperplastic, invasive, and migratory, and these features are closely related to synovial hyperplasia, joint inflammation, and joint destruction [3, 28, 29]. Therefore, we can treat RA as a special tumor-like disease. miRNAs have been proven to be key regulators that target multiple genes in various disease development and progression processes [30, 31]. Several miRNAs were observed to be abnormally expressed in RA, some of which affect RA-FLS cell proliferation, inflammation, or cellular signaling pathways [6–8]. In this study, we detected miR-449a expression and found that it was decreased in RA synovial tissue, which was consistent with the results of some studies in tumors [10, 13, 14, 32, 33]. We further studied the effect of miR-449a on RA-FLS and found that miR-449a inhibited RA-FLS cell proliferation, migration, and IL-6 production, which indicated that the dysregulation of miR-449a expression may be related to RA progression.

Previous studies found that HMGB1 was overexpressed in RA synovial tissue promoted RA-FLS
proliferation, migration, and invasion, and HMGB1-mediated autophagy decreased the sensitivity of RA-FLS to methotrexate (MTX) [18, 19]. It seems that HMGB1 plays a nonnegligible role in the pathogenesis of RA. In our study, we found that HMGB1 was regulated by miR-449a and was a direct target of miR-449a in RA-FLS, which was consistent with the study by Wu et al. [24]. They found that miR-449a inhibited cell proliferation, migration, and invasion in non-small cell lung cancer by directly targeting HMGB1. The results indicated that decreased miR-449a expression may be the main cause of HMGB1 overexpression in RA synovial tissue.

YY1 is a transcription factor with different biological functions that can either activate or repress gene expression by directly binding to the target promoters and recruiting histones and DNA modifiers [26, 34]. Recent studies have found that YY1 is overexpressed in RA patients and CIA mice [25, 26]. Mu et al. [25] identified that miR-10a, a YY1 target gene, was inhibited by YY1, which contributed to excessive NF-κB-mediated inflammatory cytokine secretion and RA-FLS migration and proliferation. Lin et al. [26] also found that YY1 promoted IL-6 transcription by directly binding to the IL-6 promoter, which contributed to RA inflammation. These studies indicated that YY1 plays an important role in RA pathogenesis. In this study, when we inhibited the expression of YY1 using an siRNA, we found that miR-449a expression was increased, and when we overexpressed YY1 in RA-FLS, the expression of miR-449a was decreased. The results indicated that YY1 negatively regulated miR-449a expression. Further study found that YY1 was also a direct target of miR-449a. Taken together, the results indicated that miR-449a and YY1 formed a mutual inhibition loop in RA-FLS. We also found that YY1 inhibited IL-6 production in RA-FLS, which was consistent with Lin’s research [26].

TNFα is a key inflammatory cytokine implicated in RA pathogenesis, and it plays a crucial role in joint destruction [35]. In recent years, the biological disease-modifying antirheumatic drugs targeting TNFα (infliximab, adalimumab) have achieved good results in clinical application, but more than half of RA patients still have no responses to the drug or unwanted side effects and eventually have to discontinue the treatment [36, 37]. Therefore, exploring the mechanism of TNFα in RA may contribute to overcoming these limitations. Mu et al. [25] found that an NF-κB/YY1/miR-10a/NF-κB regulatory circuit, which promotes excessive NF-κB-mediated inflammatory cytokine secretion and RA-FLS cell proliferation and migration, existed. In this study, we observed that TNFα promoted HMGB1 and YY1 mRNA expression and IL-6 production. After the transfection of miR-449a, the expression of HMGB1 and YY1 and the production of IL-6 were decreased. These results indicated that miR-449a acted as a regulator to inhibit TNFα-mediated HMGB1 and YY1 overexpression and IL-6 production.

Conclusions
We first demonstrated that miR-449a inhibited RA-FLS proliferation, migration, and IL-6 production by directly targeting HMGB1 and YY1. miR-449a inhibited TNFα-mediated YY1 and HMGB1 overexpression and IL-6 production and formed a mutual inhibition loop with YY1 in RA-FLS, which indicated that miR-449a was a crucial molecule in RA pathogenesis as a switch to control TNFα-mediated inflammation. As a result, miR-449a-based therapeutic strategies may offer a new treatment option for RA. Further study is needed to confirm the new option in vivo experiments.

Additional files

Additional file 1: Table S1. Sequences of oligonucleotides. (DOCX 12 kb)
Additional file 2: Figure S1. HMGB1 was overexpressed in RA synovial tissue compared with OA tissue. (DOCX 128 kb)

Abbreviations
ACR: American College of Rheumatology; CI: Confidence interval; ELISA: Enzyme-linked immunosorbent assay; HMGB1: High-mobility group box protein 1; miRNAs: MicroRNAs; MTX: Methotrexate; OA: Osteoarthritis; RA: Rheumatoid arthritis; RA-FLS: Rheumatoid arthritis fibroblast-like synoviocytes; SD: Standard deviation; YY1: Yin Yang 1

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements
We thank Le Yang and Xiaqing Wu for the synovial tissue collection.

Authors’ contributions
PX and YQ conceived of the study and analyzed the data. YC and CJ carried out the experiments, analyzed the data, participated in the study design, and drafted the article. IZ, KX, XR, PH, and LX collected the clinical patients and partly performed cell culture and miRNA-experiment expression. BW, QY, YG, and JS participated in the analysis and interpretation of data. All authors have read and approved the final manuscript.

Funding
This work was financially supported by the National Natural Science Foundation of China (No. 81772410, 81601877, and 81702119).

Availability of data and materials
All the data generated and analyzed during this study are included in this published article and are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was performed with the approval of the human research ethics committee of Xi’an Hong Hui Hospital. All patients fulfilled the ACR criteria for the classification of RA or OA and provided informed consent.

Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Orthopaedics of the First Affiliated Hospital, Xi’an Jiaotong University Health Science Center, Xi’an 710061, China. 2. Department of Joint Surgery, Xi’an Honghui Hospital, Xi’an Jiaotong University Health Science Center, Xi’an 710054, China. 3. Department of Cardiovascular Medicine of the Second Affiliated Hospital, Xi’an Jiaotong University School, Xi’an 710038, China. 4. Department of Orthopaedics of the First Affiliated Hospital of Xi’an Jiaotong University Health Science Center, Xi’an 710061, China.

Received: 1 February 2019 Accepted: 17 May 2019
Published online: 03 June 2019

References
1. Borrero CG, et al. Emerging MRI methods in rheumatoid arthritis. Nat Rev Rheumatol. 2011;7(2):85–95.
2. Scott DL, et al. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–108.
3. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233–55.
4. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11(4):441–50.
5. Vicente R, et al. Deregulation and therapeutic potential of microRNAs in arthritic diseases. Nat Rev Rheumatol. 2016;12(4):211–20.
6. Hong W, et al. The effects of microRNAs on key signalling pathways and epigenetic modification in fibroblast-like synoviocytes of rheumatoid arthritis. Mediat Inflamm. 2018;2018(2013124).
7. Hussain N, et al. Down-regulation of miR-10a-5p in synoviocytes contributes to TGB5-controlled joint inflammation. J Cell Mol Med. 2018;22(1):241–50.
8. Tavasolian F, et al. Altered expression of microRNAs in rheumatoid arthritis. J Cell Biochem. 2011;111(1):478–87.
9. Li LP, et al. miR-449a and CDK6 in gastric carcinoma. Oncol Lett. 2014;8(4):1533–38.
10. Yao Y, et al. MiR-449a exerts tumour-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein. Mol Oncol. 2015;9(3):640–56.
11. Parker MJ, Palladino MA. MicroRNAs downregulated following immune activation of rat testis. Am J Reprod Immunol. 2017;77(6):e12673.
12. Zhang YL, et al. The lncRNA XIST exhibits oncogenic properties via regulation of miR-449a and Bcl-2 in human non-small cell lung cancer. Acta Pharmacol Sin. 2015;34(3):371-81.
13. Wang BQ, et al. MicroRNA-499a decelerates glioma cell proliferation while accelerating apoptosis through the suppression of Notch1 and the MAPK signaling pathway. Brain Res Bull. 2018;142:96–106.
14. Wang H, et al. Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-00091/miR-449a pathway in breast carcinogenesis. Int J Oncol. 2018;52(3):743–54.
15. Tang D, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010;1799(1–2):131–40.
16. Tang D, et al. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal. 2011;14(7):1315–35.
17. Huang 2, et al. Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of uterine cervical cell lines via the NF-kappaB signaling pathway. Sci Rep. 2015;5:12907.
18. Xu K, et al. Autophagy induction contributes to the resistance to methotrexate treatment in rheumatoid arthritis fibroblast-like synovial cells through high mobility group box chromosomal protein 1. Arthritis Res Ther. 2015;17:374.
19. Li YB, et al. Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression. Mol Cell Biochem. 2016;402(1–2):161–70.
20. Dormoy-Racket V, et al. HuR and miR-1192 regulate myogenesis by modulating the translation of HMGB1 mRNA. Nat Commun. 2013;4:2388.
21. Liu K, et al. MiR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy. 2014;10(3):442–52.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions